Oral Presentation ASPCR-ASDR Conference 2013

Variant HSP70i with treatment potential for vitiligo (#9)

Jeffrey Mosenson 1 , Andrew Zloza 2 , Jose A Guevara-Patino 1 , I. Caroline Le Poole 1
  1. Loyola University Chicago, Maywood, IL, United States
  2. Rush University, Chicago, IL, United States
Heat shock proteins protect stressed cells from apoptosis. We reasoned that an environmental stressor inducing HSP70 expression may be associated with greater secretion by melanocytes. Extracellular stress proteins can bind dendritic cells and induce immune response to peptides bound to these molecular chaperones. Meanwhile, intracellular colocalization with melanosomal proteins explains the immunogenic cargo that leads to vitiligo development. We showed that HSP70i is central to disease development in mouse models; knockout mice do not depigment in response to antigenic challenge, whereas HSP70i alone is sufficient to induce disease in a transgenic mouse model of spontaneous depigmentation. Thus, we hypothesized that targeting HSP70i in autoimmune vitiligo is suited to halt depigmentation. We confirmed that dendritic cell profiles in human patients mimic those observed in response to HSP70i in mice. The c-terminus and a peptide within it proved crucial to  depigmentation. A single amino acid modification introduced by site directed mutagenesis was sufficient to prevent human dendritic cell activation and inhibit depigmentation in mice. Mutant HSP70i drove expansion of a regulatory subset of APC, in contrast to the inflammatory DC subset observed in response to wildtype HSP70i. Treatment was associated with reduced T cell influx to the skin, and circulating T cells maintained a memory profile not observed in response to the wildtype molecule. Mutant HSP70i likewise affected profiles of immune cells collected  from cultured human skin explants. Taken together, our data support the remarkable treatment potential of mutant HSP70i for vitiligo.